A greater understanding of the actions of SphK1/S1P in the context of diabetes, especially the onset of type 2 diabetes and cancer, is required if we are to switch the sphingolipid rheostat in the treatment of diabetes and cancer comorbidity from a problem to an advantage. This evidence concerns the gene SPHK1 and diabetes mellitus.